| |
|
|
|
Xtalks, Online
2025-11-24
Delaying the design and execution of an evidence strategy can lead to irreversible consequences for market access, pricing and health technology assessment outcomes. This webinar explores the strategic value of early evidence generation in biotech development, focusing on what data is needed, when it matters and how emerging companies can build a fit-for-purpose plan to support both partnerships and reimbursement goals.
Drawing from real-world examples and market trends, this webinar highlights the risks of poor planning and the benefits of early, integrated evidence strategies. It will outline what constitutes “fit-for-purpose” data, when it is needed and how to align evidence generation with business development and reimbursement goals. Attendees will learn how timely evidence planning can reduce uncertainty, support pricing and access and enhance partnership potential.
Register for this webinar to discover why delaying evidence generation by even two years can cost you access, pricing and partnerships.
Keywords: Clinical Data, Clinical Research, Commercialization/HEOR/Market Access, CRO, Data Analytics, Drug Pricing, Evidence Strategy, HTA, Real-World Data, Real-World Evidence, Regulatory, Reimbursement
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Noolie Gregory, Head of Evidence Generation, Sciensus
Andrew Cummins, Vice President, Business Development, Sciensus
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-11-24
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|